Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis

Table 3 Symptom improvement across groups, median (interquartile range)

GCSI	Control group (n = 92)	Research group (n = 106)	Z	P value
Nausea and vomiting (points)
Before intervention	2.00 (1.00, 3.00)	2.00 (1.00, 4.00)	-1.405	0.160
After intervention	2.00 (1.00, 2.00)	1.00 (1.00, 2.00)	-3.868	< 0.001
Stomach distension (points)
Before intervention	2.00 (1.00, 3.00)	2.00 (1.75, 3.00)	-0.538	0.591
After intervention	1.00 (1.00, 2.00)	1.00 (0.00, 1.00)	-5.929	< 0.001
Inability to eat a normal amount of food (points)
Before intervention	3.00 (2.00, 4.00)	3.00 (2.00, 4.00)	-1.257	0.209
After intervention	3.00 (2.00, 3.75)	2.00 (1.75, 3.00)	-2.096	0.036
Inappetence (points)
Before intervention	2.00 (2.00, 3.00)	2.00 (2.00, 3.00)	-0.172	0.863
After intervention	1.00 (1.00, 2.00)	1.00 (1.00, 2.00)	-2.192	0.028
Severe postprandial fullness (points)
Before intervention	2.00 (1.00, 2.00)	2.00 (2.00, 2.00)	-1.533	0.125
After intervention	1.00 (1.00, 2.00)	1.00 (0.75, 1.00)	-3.761	< 0.001

GCSI: Gastroparesis Cardinal Symptom Index.